(Q34475383)

2 August 2017

0 references

Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease (English)

1 reference

autosomal dominant polycystic kidney disease

2 August 2017

main subject

0 references

1 reference

6

Rafael Selgas

1 reference

2 August 2017

Ramón Peces

1

1 reference

2 August 2017

Carlos Peces

2

1 reference

2 August 2017

Virginia Pérez-Dueñas

3

1 reference

2 August 2017

Emilio Cuesta-López

4

1 reference

2 August 2017

Sebastián Azorín

5

1 reference

2 August 2017

publication date

16 January 2009

1 reference

2 August 2017

1 reference

2 August 2017

volume

2

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

133-135

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

2 August 2017

copyright license

start time

3 October 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Sirolimus reduces polycystic liver volume in ADPKD patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4421355

Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4421355

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4421355

A successful treatment of life-threatening bleeding from polycystic kidneys with antifibrinolytic agent tranexamic acid.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4421355

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4421355

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4421355

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4421355

Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease

27 October 2018

1 reference

12 December 2020

Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study

1 reference

12 December 2020

Volume progression in polycystic kidney disease

1 reference

12 December 2020

Tranexamic acid and uremic bleeding: evidence-based treatment recommendations

1 reference

12 December 2020

Identifiers

DOI

10.1093/NDTPLUS/SFN210

1 reference

2 August 2017

1 reference

2 August 2017

1 reference